Related references
Note: Only part of the references are listed.Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists
Anke-Katrin Volz et al.
PHARMACEUTICAL RESEARCH (2020)
Single-and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
Patricia N. Sidharta et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
NONMEM Tutorial Part II: Estimation Methods and Advanced Examples
Robert J. Bauer
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity
Xu Steven Xu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension
Andreas Krause et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2018)
Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions
Ruben de Kanter et al.
CLINICAL PHARMACOKINETICS (2016)
Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
P. N. Sidharta et al.
CLINICAL PHARMACOKINETICS (2015)
Pharmacokinetic-Pharmacodynamic Relationships of Macitentan, a New Endothelin Receptor Antagonist, After Multiple Dosing in Healthy Korean Subjects
Li Young Ahn et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2014)
Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension
Jasper Dingemanse et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Pharmacokinetics of the Novel Dual Endothelin Receptor Antagonist Macitentan in Subjects With Hepatic or Renal Impairment
Patricia N. Sidharta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects
Jacob Atsmon et al.
CLINICAL PHARMACOKINETICS (2013)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of macitentan, an Endothelin Receptor Antagonist, in an Ascending Multiple-Dose Study in Healthy Subjects
Patricia N. Sidharta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Pharmacokinetics of Macitentan in Caucasian and Japanese Subjects: The Influence of Ethnicity and Sex
Shirin Bruderer et al.
PHARMACOLOGY (2013)
Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans
Shirin Bruderer et al.
XENOBIOTICA (2012)
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Martin Bergstrand et al.
AAPS JOURNAL (2011)
Macitentan: entry-into-humans study with a new endothelin receptor antagonist
Patricia N. Sidharta et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan
Oliver Kummer et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Mechanism-based concepts of size and maturity in pharmacokinetics
B. J. Anderson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Likelihood based approaches to handling data below the quantification limit using NONMEM VI
Jae Eun Ahn et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Drug therapy: Treatment of pulmonary arterial hypertension
M Humbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
